AstraZeneca

MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment

WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …

MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More